Ipsen (($GB:0MH6)) announced an update on their ongoing clinical study. Study Overview: Ipsen is launching a new study titled ‘Registry to ...
Metabolic dysfunction-associated steatohepatitis (MASH) is a silent liver disease that is caused by fat buildup, inflammation ...
High blood pressure, diabetes and low levels of "good" HDL cholesterol all increase the risk of death for people with fatty ...
Mayo Clinic scientists uncovered how excessive drinking triggers fatty liver disease by disrupting the enzyme VCP, which ...
Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive ...
The condition occurs when fat builds up in the liver, eventually causing tissue damage and scarring. It usually is associated ...
More than a third of the world's population is affected by metabolic dysfunction-associated steatotic liver disease, or MASLD ...
A new analyst survey suggests that doctors are still prescribing Sarepta’s Elevidys, even after a series of deaths in certain ...
The biotech has paused its Phase I trial of CAP-002, pending investigation into the “root cause” of the death.
Toxic “forever chemicals” are altering human liver function at a fundamental level by triggering both fat accumulation and ...
While Sarepta Therapeutics shares registered a modest gain of 1.35% to $18.71 in recent trading, this minor uptick belies the profound challenges confronting the biotechnology firm. A series of ...
Amid an unprecedented turnover in leadership at the FDA and mass layoffs of staff, communication has crumbled and uncertainty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback